We are live on
!
Find out more
EC
EcoR1 Capital Portfolio holdings
AUM
$2.06B
Turnover
46.34%
1-Year Est. Return
215.32%
This Fund
S&P 500
This Quarter
Est. Return
+30.44%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$318M
AUM Growth
+$98.7M
(+45%)
Cap. Flow
+$13.5M
Cap. Flow
% of AUM
4.23%
Top 10 Holdings %
Top 10 Hldgs %
67.71%
Holding
36
New
11
Increased
7
Reduced
7
Closed
5
Avg Time Held Equity + Options
0.4
years
Top 10 Avg Time Held Equity + Options
0.3
years
Top 20 Avg Time Held Equity + Options
0.5
years
Avg Time Held Equity only
0.5
years
Top 10 Avg Time Held Equity only
0.4
years
Top 20 Avg Time Held Equity only
0.6
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Kura Oncology
KURA
|
+$19.3M |
| 2 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
+$19.1M |
| 3 |
Cytokinetics
CYTK
|
+$13.9M |
| 4 |
Ironwood Pharmaceuticals
IRWD
|
+$9.48M |
| 5 |
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$8.55M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Atara Biotherapeutics
ATRA
|
+$25.3M |
| 2 |
EPZM
Epizyme, Inc
EPZM
|
+$11.8M |
| 3 |
KITE
Kite Pharma, Inc.
KITE
|
+$8.12M |
| 4 |
CASC
Cascadian Therapeutics, Inc.
CASC
|
+$2.58M |
| 5 |
OREX
Orexigen Therapeutics, Inc.
OREX
|
+$1.98M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 77.71% |
| 2 | Miscellaneous | 22.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Akari Therapeutics
AKTX
$20.2M
| $1.46M | 0.46% |
126
| – | – |
2015 Q3
1 quarter
|
|
27
CALL
Gilead Sciences
GILD
$195B
| $1.19M | 0.38% |
11,800
+8,545
| +263% | +$889K |
2015 Q3
1 quarter
|
|
|
NRX
28
DELISTED
NEPHROGENEX INC COM
NRX
| $941K | 0.3% |
+588,235
| New | +$1.37M |
2015 Q4
0 quarters
|
|
29
DELISTED
QLT Inc
QLTI
| $266K | 0.08% |
100,000
-538,900
| -84% | -$1.52M |
2015 Q2
2 quarters
|
|
30
CALL
Larimar Therapeutics
LRMR
$207M
| $63K | 0.02% |
+833
| New | +$134K |
2015 Q4
0 quarters
|
|
|
31
Atara Biotherapeutics
ATRA
$96.9M
| – | – |
-32,138
| Closed | -$25.3M | – |
|
32
Gyre Therapeutics
GYRE
$679M
| – | – |
-498
| Closed | -$261K | – |
|
33
CALL
DELISTED
Regulus Therapeutics
RGLS
| – | – |
-11
| Closed | -$35K | – |
|
|
CASC
34
DELISTED
Cascadian Therapeutics, Inc.
CASC
| – | – |
-157,250
| Closed | -$2.58M | – |
|
|
OREX
35
DELISTED
Orexigen Therapeutics, Inc.
OREX
| – | – |
-93,796
| Closed | -$1.98M | – |
|
Similar funds
RHJA
ST
ABTD
CFA
DWT
RMC
SIC
FWTB
EcoR1 Capital's Q4 2015 Portfolio in Review
As of Q4 2015, EcoR1 Capital held 36 positions worth $318M, up 45% from $220M the previous quarter. Its ten largest holdings account for 68% of the portfolio.
EcoR1 Capital deployed $13.5M of net new capital in Q4 2015, opening 11 new positions and adding to 7 existing holdings. Its largest new stake was Kura Oncology: 2,450,000 shares worth $20.6M.
By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 88% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Epizyme, Inc, an estimated $11.8M trimmed.
- EcoR1 Capital's largest Q4 2015 buy was Kura Oncology: 2,450,000 shares worth $20.6M.
- EcoR1 Capital added most to Five Prime Therapeutics, Inc. in Q4 2015, an estimated $19.1M increase.
- EcoR1 Capital's biggest Q4 2015 reduction was Epizyme, Inc, cutting an estimated $11.8M.
- EcoR1 Capital fully exited Atara Biotherapeutics in Q4 2015, selling an estimated $25.3M.
- EcoR1 Capital's ten largest holdings make up 68% of its $318M portfolio in Q4 2015.
- EcoR1 Capital opened 11 new positions and closed 5 in Q4 2015.
- EcoR1 Capital's portfolio value rose 45% quarter-over-quarter to $318M.
Based on EcoR1 Capital's 13F filing for Q4 2015, filed 16 Feb 2016.